Page 2 - Nonclinical Development News Today

Corporate restructuring underway and MASTERS-2 clinical trial prioritizedConference call begins at 4:30 p.m. Eastern time todayCLEVELAND--(BUSINESS WIRE)--$ATHX #ARDS--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.S...

Press release content from Business Wire. The AP news staff was not involved in its creation.

CLEVELAND--(BUSINESS WIRE)--$ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health...

The pre-IND meeting takes place when a sponsor presents their planned Phase 1 study design, including their proposed product development plan and...

GuruFocus Article or News written by Marketwired and the topic is about:

Published: May 05, 2021 NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.  . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senio...

January Therapeutics Announces Appointment of Dr. Daniel C. Maneval, PhD as Chief Scientific Officer Share Article As Chief Scientific Officer Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs SAN DIEGO (PRWEB) April 27, 2021 January Therapeutics today announced the appointment of Daniel C. Maneval, PhD, as Chief Scientific Officer. Dr. Maneval will lead key aspects of the Scientific Team...

April 20, 2021) Inhalation Sciences (ISAB) has signed an agreement with prestigious lead generation company Cience and with Coelus Bio, a boutique CRO consulting firm specialized in inhalation drug development, to generate new leads and sales in the US. It is part of the marketing activities aimed at growing ISABs sales and presence in the US, a strategic goal for 2021, and becoming a clear market leader in its niche. With strengthened sales in 2020 ISAB identified expanding its marketing and ...

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development News provided by Share this article Share this article Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company. WALTHAM, Mass., April 13, 2021 /PRNewswire/ -- Skyhawk Therapeutics today announced the appoin...

Share this article Share this article NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinsons Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinsons disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the ...